Prodromal Inclusion/Exclusion Criteria O of 10 completed **Assessment Date** 10/29/2020 **Inclusion Criteria** 1. Enrolled in PPMI 2.0 Remote and based on remote assessments, including hyposmia, are eligible for PPMI 2.0 Clinical. No Yes 2. Male or female age 60 years or older (except age 30 years or older for SNCA, or rare genetic mutations (such as Parkin or Pink1) participants). Yes No 3. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 halflives before DaTscan imaging. No Yes 5. Able to provide informed consent. No Yes 6. Women may not be pregnant, lactating or planning pregnancy during the study. No Yes

Includes a negative pregnancy test on day of Screening DaTscan imaging test prior to injection of DaTscan.

Exclusion Criteria	
Clinical diagnosis of PD, other parkinsonism No	m, or dementia. Yes
2. Received any of the following drugs: dopar and reserpine within 6 months of Screening No	mine receptor blockers (neuroleptics), metoclopramide g visit. Yes
Current treatment with anticoagulants (e.g preclude safe completion of the lumbar pu No	., coumadin, heparin, oral thrombin inhibitors) that might ncture. Yes
4. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia. No Yes	
 5. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation. No Yes 	